CAS: 14686-89-6; 1,2:5,6-Di-O-Isopropylidene-A-D-Gulofuranose

相似化合物

2595-05-3 79943-22-9 16713-80-7

上下游产品

CAS号26775-14-4 3-O-acetyl-1,2:... | CAS号2847-00-9 1,2:5,6-二-O-异亚丙... | CAS号3253-75-6 a-D-Glucofurano... | CAS号582-52-5 双丙酮葡萄糖 | CAS号74-96-4 溴乙烷 | CAS号14686-88-5 3-O-乙酰基-1,2:5,6... | CAS号116408-84-5 (3aR,5R,6S,6aR)... | CAS号116384-37-3 (3aR,5R,6S,6aR)... | CAS号143986-03-2 (3aR,5R,6R,6aR)... | CAS号4546-55-8 N6-苯甲酰基腺苷 | CAS号22331-21-1 3-O-苄基-1,2:5,6-... | CAS号2847-00-9 1,2:5,6-二-O-异亚丙... | CAS号23202-81-5 甲基-5-脱氧-2,3-O-异... | CAS号13964-23-3 3-叠氮基-3-脱氧-1,2:... | CAS号31795-13-8 1,2-o-异亚丙基-3-o-... | CAS号31001-26-0 3-fluoro-3-deox... | CAS号14086-88-5 3-乙酰氨基-3-脱氧-D-葡萄糖 | CAS号23558-05-6 3-O-苄基-1,2-O-异亚... | CAS号7508-81-8 a-D-Glucofurano...

双丙酮葡萄糖置于ruthenium Trichloride,Sodium Tetrahydroborate,Potassium Metaperiodate,Celite,Ammonium Chloride,Potassium Carbonate体系中,化学反应生成二丙酮-D-葡萄糖
参考文献:(-)-Litsenolides C-1和c-2的总合成
标题:(-)-Litsenolides C-1和c-2的总合成
摘要:描述了由d-葡萄糖以12%的总收率合成(-)-Litsenolides C 1和c 2的方法,其中α-亚烷基双键是通过c-2含碳水合物衍生物的wittig反应形成的.
Doi:10.1039/p19870002681

专利信息

专利号:US-2023137160-A1
优先权日:2020-03-31
标 题 :Large scale process for preparing 1,2,4, 6-tetra-o-acetyl-3-azido-3-deoxy-d-galactopyranoside
发明人：NILSSON ULF; CUMMINS JONATHAN
权利人:GALECTO BIOTECH AB
摘要:A process for preparing a compound of formula (X) n n n n n n n n n n The process includes reacting a compound of formula (IX) n n n n n n n n n n with an acetylating agent in the presence of a base in a suitable solvent and at a suitable temperature for a sufficient reaction time for preparing the compound of formula X. The process is suitable for large scale synthesis.

专利号:US-8846910-B2
优先权日:2006-08-22
标题:Matrix metalloproteinase inhibitors
发明人：SATTIGERI VISWAJANANI J; PALLE VENKATA P; KHERA MANOJ KUMAR; REDDY RANADHEER; TIWARI MANOJ KUMAR; SONI AJAY; RAUF ABDUL REHMAN ABDUL; JOSEPH SONY; MUSIB ARPITA; DASTIDAR SUNANDA G; SRIVASTAVA PUNIT KUMAR
权利人:RANBAXY LAB LTD
摘要:The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.